Shanxi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	862.9M	870.8M	846.6M	799.3M	829.0M
Cost of Revenue	286.0M	284.0M	280.2M	257.5M	250.9M
Gross Profit	576.8M	586.7M	566.4M	541.8M	578.1M
Operating Expenses
R&D Expense	50.6M	50.8M	56.5M	50.0M	54.5M
SG&A Expense	—	—	—	—	—
General & Admin Expense	149.0M	143.5M	125.9M	121.5M	116.5M
Selling & Marketing Expense	263.1M	272.6M	302.5M	332.0M	417.6M
Other Expenses	—	—	—	—	—
Total Operating Expenses	495.2M	500.3M	512.1M	545.7M	643.9M
Cost and Expenses	781.3M	784.3M	792.3M	803.2M	894.7M
Operating Income (EBIT)	68.1M	79.8M	65.0M	40.2M	(115.1M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	81.9M	90.8M	80.6M	55.3M	(90.0M)
Income Tax Expense	36.7M	34.4M	5.9M	6.6M	7.9M
Bottom Line
Net Income	17.8M	24.9M	42.2M	25.2M	(118.5M)
Earnings from Cont. Ops	47.9M	59.6M	75.9M	48.7M	(97.9M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	17.8M	24.9M	42.2M	25.2M	(118.5M)
Per Share
Basic EPS	CN¥0.07	CN¥0.10	CN¥0.17	CN¥0.10	(CN¥0.50)
Diluted EPS	CN¥0.07	CN¥0.10	CN¥0.17	CN¥0.10	(CN¥0.50)
Revenue Per Share	CN¥3.54	CN¥3.59	CN¥3.50	CN¥3.31	CN¥3.50
Shares
Basic Shares Outstanding	244.0M	242.7M	241.6M	241.6M	237.1M
Diluted Shares Outstanding	244.0M	242.7M	241.6M	241.6M	237.1M
Profitability Metrics
EBITDA	—	133.7M	117.5M	93.6M	(56.0M)
D&A	—	54.0M	52.5M	53.4M	59.0M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026